Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Calcium Overloading-Induced UBE2O Upregulation Alleviates Neuronal Apoptosis.

Molecular neurobiology·2026
Same author

ZER1 Restrains Pressure Overload-Induced Cardiac Remodeling by Targeting DVL2 for Gly/N-Degron-Dependent Degradation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Duration-dependent effects of sucrose intake on fear extinction via distinct mechanisms in the amygdala and hippocampus.

Brain research·2026
Same author

Synthesis of aza-β-lactams <i>via</i> B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>-catalyzed Wolff rearrangement/[2 + 2] cascade cyclization of α-diazoketones with diazenes.

Organic & biomolecular chemistry·2026
Same author

Deep Learning for Classifying and Cognitive Profiling of Subcortical Vascular Cognitive Impairment.

Cyborg and bionic systems (Washington, D.C.)·2026
Same author

Multimodal clocks of human aging.

Cell·2026

関連する実験動画

Updated: Sep 12, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K

アルツハイマー病の免疫療法の改善

Mengen Xing1, Weihong Song1,2

  • 1Center for Geriatric Medicine, International Center for Alzheimer's Research, Prevention and Treatment, The First Affiliated Hospital and Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Science (New York, N.Y.)
|August 7, 2025
PubMed
まとめ

アミロイドベータ (Aβ) ペプチドを標的とした新しい改変抗体は,臨床前アルツハイマー病の研究で安全性と有効性の改善を示した. この抗体は,Aβ病理に対する将来の治療開発に希望を示しています.

さらに関連する動画

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.1K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

関連する実験動画

Last Updated: Sep 12, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.1K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

科学分野:

  • 神経科学
  • 免疫学
  • 薬理学について

背景:

  • アミロイドベータ (Aβ) プラークはアルツハイマー病 (AD) の特徴です.
  • 現在のAβ標的治療は,アミロイド関連画像異常 (ARIA) のような有害事象を引き起こす可能性があります.

研究 の 目的:

  • 副作用を軽減したAβ標的化のための改変した抗体を開発し評価する.
  • ADのマウスモデルにおけるこの改変抗体の有効性と安全性を評価する.

主な方法:

  • Aβとの相互作用を変化させるための特定の改変による抗体を設計する.
  • Aβ病理を示す変異性マウスに変異性抗体を投与する.
  • Aβプラーク負荷,認知機能,有害事象の発生率の評価

主要な成果:

  • 改変した抗体は,対照群と比較してAβプラークの負荷を著しく減少させた.
  • ARIAなどの有害事象の有意な減少が観察されました.
  • 認知能力の改善は,Aβの病理性の低下と相関していた.

結論:

  • 抗体改変は,マウスモデルでAβに対する治療効果を高めることができます.
  • このアプローチは,Aβを標的とするAD治療の安全性プロファイルを改善する可能性を示しています.